A novel caspase-3-specific inhibitory peptide and an agonistic peptide that binds to the Fas molecule were discovered using our computer screening strategy called the amino acid complement wave ( 
INTRODUCTION
Apoptosis is an essential process of the development and tissue homeostasis of multicellular organisms. [1] [2] [3] [4] The deregulation of apoptosis has been suggested to be involved in the pathogenesis of many diseases, such as cancers, autoimmune diseases, and neurodegenerative disorders. 2, 5) A number of apoptosis pathways are mainly initiated through death receptors such as the tumor necrosis factor (TNF) receptor, Fas (APO-1/CD95), and TNF-related apoptosis-inducing ligand (TRAIL) receptor, [6] [7] [8] or mitochondria, 9, 10) resulting in activation of initiator/effector caspases 11, 12) and DNA endonucleases, such as caspase-activated DNase (CAD), DNase g, and endonuclease G. [13] [14] [15] Furthermore, the death signaling pathways are strictly regulated by protein factors, such as Bcl-2 and the inhibitor of apoptosis protein (IAP) family proteins. 16, 17) Therefore these molecules are potential therapeutic targets for pharmaceutical manipulation of apoptosis.
Because of the critical roles played by the Fas ligand (FasL)/Fas system and caspases in apoptosis, these molecules are important targets for developing novel therapeutic agents. [18] [19] [20] Among various strategies to develop proteinbased therapies, monoclonal antibody (mAb) technology has been used in development of potential clinical reagents. [18] [19] [20] [21] However, these protein-based therapeutics have poor bioavailability. One useful approach to overcome the limitation of mAb therapeutics is to develop small molecular agents such as peptides and peptidomimetic forms. Since the specific interactions between FasL and Fas or death substrates and caspases have been determined by specific regions at the surfaces of these molecules as critical epitopes, 22, 23) it could be possible to develop small peptides that bind to the epitopes and have biological activities. A number of studies indicated that computationally designed complementary peptides bind to a target protein. 24, 25) We are interested in the development of new methodologies of structure-based drug design (SBDD) for the discovery of small molecules that regulate protein-protein interactions. 26) Since the interactions between proteins generally involve large interface regions, rational design of small molecules effectively binding to these surfaces has long been considered to be difficult. Recent studies, however, have indicated that protein-protein interactions occur through small surface binding epitopes. 22, 23, [27] [28] [29] Thus small peptides that have high affinities to such small binding epitopes may be sufficient for the regulation of large protein-protein interactions. Computer-aided structure-based design of peptides based on molecular complementarity to a target protein could discover functional peptides. In this study, we tested such a hypothesis by targeting the main apoptosis-related molecules, Fas and caspase-3. SBDD of optimized small peptides has important implications for the study of apoptosis regulatory mechanisms and the development of potential new therapeutic agents.
MATERIALS AND METHODS
Materials Ac-DEVD-CHO was purchased from the Peptide Institute, Inc. Ac-DEVD-pNA and recombinant human caspase-3 were from Calbiochem. Ac-DNLD-CHO was synthesized by the Peptide Institute, Inc. Fas reactive peptide (FRAP-4) and (FRAP-4) 8 -MAP were synthesized by Sigma-Genosys, Inc.
Cell Culture The Jurkat cell line was purchased from the American Type Culture Collection (Rockville, MD, U.S.A.). The NOS4 cell line was established from a patient with serous ovarian cytodermocarcinoma. 30) The cells were cultured in RPMI-1640 (Jurkat) or Dulbecco's modified Eagle's medium (DMEM) (NOS4) containing 10% fetal bovine serum (FBS), penicillin 100 mg/ml, and streptomycin 100 mg/ml. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 and 95% air.
Caspase-3 Inhibition Assay To determine the inhibitory potencies of tetrapeptide inhibitors against caspase-3, an in vitro caspase activity assay was performed. The activity of caspase-3 was measured using Ac-DEVD-pNA as a substrate. One unit of active recombinant human caspase-3 was incubated with peptide inhibitor at the indicated concentrations in assay buffer [100 mM NaCl, 50 mM HEPES (pH 7.4), 10 mM DTT, 1 mM EDTA, 10% glycerol, and 0.1% CHAPS] at 25°C for 30 min with shaking in a 96-well assay plate (Corning). Then, 100 mM Ac-DEVD-pNA was added to each well and the absorbance at 405 nm at 25°C was measured using a 96-well plate reader Wallac 1420 ARVOsx (PerkinElmer) at 1-min intervals for 60 min.
DNA Fragmentation Assay Cells were lysed in lysis solution [50 mM Tris-HCl (pH 7.8), 10 mM EDTA, 0.5% sodium N-lauroyl sarcosinate] and then treated successively with RNase A 0.5 mg/ml for 30 min at 50°C and proteinase K 0.5 mg/ml for 30 min at 50°C. DNA thus prepared was loaded in 2% agarose gels containing ethidium bromide 0.5 mg/ml for 1 h at a constant 100 V. DNA fragmentation was examined in photographs taken under UV illumination and percent fragmentation was determined with densitometoric analysis as described previously.
31)
Flow Cytometric Analysis Apoptosis was routinely measured by determining the DNA content of cells using propidum iodide (PI) staining and flow cytometry, as previously described. 32) Briefly, after harvesting, the cells were fixed with 70% ethanol for 30 min on ice, treated with RNase A 0.1 mg/ml for 20 min at 37°C, and then stained with PI 25 mg/ml for 20 min on ice. The samples were analyzed using flow cytometry (Calibur, B.D.). Percentages of apoptotic cells containing less DNA than 2 N in total cells were calculated.
Computer-Aided Structure-Based Design of Peptides (ACW Method) Identification of target sequences was carried out using the receptor-binding domain (RBD) method. 33) The number (n) of the target sequence is assigned to the length of amino acids of the complementary peptide. Thus the total number of candidates for complementary peptides is 20 n . A schematic overview of the amino acid complement wave (ACW) method is shown in Fig. 1 . In the first screening, complementary peptides are selected by a complement indicator (R). The indicator between a target sequence and a candidate for complementary peptides is defined as follows:
where w is the number of residues in the window, j is (s) to (nϪsϪ1), and s is w/2 (w: even number) or (wϪ1)/2 (w: odd number). T i and C i are an index of amino acid i for the target sequence and candidate peptides, respectively. In the present study, Eisenberg's consensus hydrophobicity scale 34) is used as the amino acid index. The window is moved along the sequence, and at each step x j and y j values are assigned. The x j and y j values are called the moving average profile wave. The window size used for calculations generally ranges from 1 to 9 residues. In this stage, 100 complementary peptides with an R value of less than Ϫ0.9 are selected.
In the second screening, the binding free energies (DG) between a target molecule and 100 complementary peptides (RϽϪ0.9) are calculated using AutoDock3.0, 35) running on a Compaq Alpha workstation. For the docking a grid spacing of 0.375 Å and 60ϫ60ϫ60 number of points are used. The grid is centered on the mass center of the experimental bound peptide or predicted binding region of the ligand molecule derived from its receptor/ligand complex model. The
LGA method is adopted using the default settings. Kollman atom charges are assigned to the target molecule and the peptides, and the rotational bonds of the peptides are defined with AutoTors. Finally, a peptide with the lowest DG is defined as an optimized complementary peptide against the target sequence. cific inhibitory peptide, we developed the new strategy of the ACW method (Fig. 1) . In this method, the number (n) of the amino acid residues in the target sequence of the caspase-3 active pocket was determined to be 4 from its biochemically predicted active site ( Fig. 2A) . One hundred tetrapeptides with the top of complement indicator (R) were selected from a 20 4 comprehensive peptide library (first screening) ( Table  1 ). The crystal structure of the caspase-3/DEVD complex (code no. 1PAU) (Fig. 2B ) was used to validate the quality of predicted binding modes of tested peptides and their binding affinities (DG).
RESULTS

Design of
One hundred peptides thus selected were next docked in the active site of caspase-3 and their DG values were calculated using the molecular docking program (second screening).
35) The most potent complementary peptide sequence was predicted to be DEVD (DGϭϪ16.15 kcal/mol) ( Table 1 , Fig. 2C ), which is a well known caspase-3 inhibitor. It should be noted that a novel sequence DNLD, which has Asn in the P3 position (Fig. 2B) , was also predicted to have potent inhibitory activity (DGϭϪ15.45 kcal/mol) ( Table 1 , Fig. 2C ).
Inhibitory Effect of DNLD on Caspase-3 and Apoptosis To evaluate the inhibitory effect of DNLD on caspase-3 activity, recombinant active caspase-3 was treated with various concentrations of Ac-DNLD-CHO. As shown in Fig. 3 , Ac-DNLD-CHO inhibited caspase-3 in a dose-dependent manner. At 30 nM, Ac-DNLD-CHO caused the inhibition of caspase-3 activity in more than 90% of the control. The IC 50 value was calculated to be 3.17 nM. The potency of Ac-DNLD-CHO was slightly weaker than that of a well-known peptide inhibitor, Ac-DEVD-CHO (IC 50 ϭ1.34 nM).
We next examined whether Ac-DNLD-CHO can inhibit apoptosis at the cellular level. Jurkat cells were preincubated with Ac-DNLD-CHO for 1 h, treated with the apoptosis inducer camptothecin, and incubated for 5 h. Aliquots of cell lysates were subjected to agarose gel electrophoresis. As shown in Fig. 3B , Ac-DNLD-CHO inhibited internucleosomal DNA fragmentation in a dose-dependent manner. At 100 mM, the DNA fragmentation was almost completely inhibited.
Design of FasL Mimic Peptide Using the ACW Method
The three-dimensional structure of FasL/Fas interaction (Fig.  4A) can be predicted from the structure of the homologous TRAIL/TRAILR (DR5) complex in the Protein Data Bank (code no. 1DU3). The most essential region in the Fas molecule for FasL binding has been biochemically determined (Fig. 4B) . 22) To define the interacting core domain in Fas, the RBD method was used. 33) Using this method, amino acid residues, S, K, C, and R present in the left-upper region, where amino acids with low hydrophobicity/high hydrophobic moment considered to be involved in protein-protein interactions appear, were predicted to interact with the FasL molecule (Fig. 4C) . Interestingly, this SKCR sequence occurs in the center of the biochemically determined interaction region (Fig. 4B) . Therefore we focused on potential peptide ligands that specifically interact with the SKCR domain in the Fas molecule.
Based on the docking study carried out with AutoDock3.0, 35) the WEWT sequence, which was selected in the first screening (Fig. 5A) , was found to have the highest binding affinity to the Fas surface pocket, as judged by the binding free energy (DG) (second screening). To gain a better understanding of how the peptide interacts with Fas, the binding mode on the SKCR domain is shown in Fig. 5B . The complement indicator (R) of WEWT to the SKCR domain was Ϫ0.92, and DG was calculated to be Ϫ9.66 kcal/mol.
FRAP-4 Octamer Induces Apoptosis of NOS4 Cells
The ability of FRAP-4 to bind to Fas for its apoptosis-inducing function raises the possibility that FRAP-4 may trigger apoptosis in cells. To examine the apoptosis induction of FRAP-4, Fas-expressing human ovarian cancer NOS4 cells were treated with various concentrations of FRAP-4 for 24 h. FRAP-4 monomer had a little ability to induce apoptosis at the higher concentrations (Fig. 6 ). Since the death signaling from Fas begins with the binding of FasL trimer to trimerize Fas molecules, FRAP-4 was multimerized by the lysine polymer MAP-8-branch with a spacer (YGI). As shown in Fig. 6 , the octamer of FRAP-4 (FRAP-4) 8 -MAP significantly induced apoptosis in a dose-dependent manner. Treatment with 10 mM of (FRAP-4) 8 -MAP for 24 h resulted in 58% inhibition of apoptosis. MAP alone did not induce apoptosis. On the basis of these results, FRAP-4 is able to induce cell death by apoptosis. 
DISCUSSION
In this study, we developed a new virtual screening strategy, the ACW method. Using this method, we identified a novel peptide inhibitor of caspase-3 (DNLD) and an agonistic peptide (FRAP-4) to the Fas molecule. The inhibitory activity of Ac-DNLD-CHO against caspase-3 was almost the same as that of the well known inhibitor Ac-DEVD-CHO. Furthermore, this peptide inhibited apoptosis at the cellular level. On the other hand, FRAP-4 (WEWT) displayed specific binding to the surface functional core domain (SKCR) in Fas, which is the center of its main interaction region with FasL. The octamer of the FasL mimic peptide, (FRAP-4) 8 -MAP, was able to induce apoptosis of human ovarian cancer NOS4 cells. These results strongly suggest that the computer screening strategy developed here is effective in identifying novel small peptides specifically bound to target proteins.
The apoptosis induction of (FRAP-4) 8 -MAP was characterized using NOS4 cells. NOS4 cells were used to test the effect of the peptides, because Fas expressed in these cells has been shown to induce apoptosis with anti-Fas antibody treatment.
36) (FRAP-4) 8 -MAP 10 mM induced extensive apoptosis in these cells, suggesting that the peptide could effectively trigger the death signal, presumably by inducing Fas trimerization. Several lines of evidence support this mechanism of action of (FRAP-4) 8 -MAP: i) FRAP-4 binds tightly to the surface functional domain in Fas in silico; ii) morphologic changes and internucleosomal DNA fragmentation characteristics of apoptosis occur after (FRAP-4) 8 -MAP treatment; and iii) induction of apoptosis by (FRAP-4) 8 -MAP involves the activation of caspases-8, -9, and -3, followed by Bid and PARP cleavages (data not shown).
To our knowledge, both DNLD and FRAP-4 are the first reported novel peptides rationally designed using the new ACW method. Although there are limitations to our method, the initial result targeting caspase-3 and Fas are encouraging. Synthetic small peptides offer powerful tools for the study of many signaling pathways. The physiologic importance of each caspase and the mechanisms by which Fas and related death receptors regulate apoptosis are still not fully defined. The DNLD and FRAP-4 designed here should be useful for further elucidation of caspase and FasL/Fas functions and mechanisms. Furthermore, these optimized peptides represent promising leads for the development of more potent and specific peptide mimics and nonpeptide organic compounds targeting caspase-dependent and death receptor-mediated apoptosis implicated in human diseases, such as neurodegenerative disorders, cancers, and autoimmune diseases.
Extensive efforts to design the regulatory (agonist/antagonist) small molecules against validated target proteins such as TRAIL receptor DR4 or DR5, the IAP and Bcl-2 families, and DNase g are currently ongoing in our laboratory. Other existing methods such as random-phase display and highthroughput screening of synthetic combinatorial libraries can be both costly and time-consuming. In contrast, the virtual design in silico of small molecules based on the three-dimensional structures of target proteins can reduce the time and cost. Thus novel methodologies for SBDD will enable us to generate lead compounds, which are expected to have enhanced affinities and decreased side effects, and to create effective chemical pharmaceuticals.
